A FRESH PERSPECTIVE

Your world, made clearer.

Explainers / Analysis · Global

What WHO’s 2027 Southern Hemisphere flu vaccine recommendation changes, and what it cannot settle

WHO set its recommended viral composition for 2027 Southern Hemisphere influenza vaccines on 25 September 2026. The decision matters for strain selection, but approvals, manufacturing and real-world performance are still separate later steps.

WHO’s 25 September 2026 recommendation for the 2027 Southern Hemisphere influenza season matters because it tells manufacturers which virus components to target next, but it does not mean finished vaccines are already approved or available. For egg-based vaccines, WHO recommended A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like and B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like viruses. For cell culture-, recombinant protein- or nucleic acid-based vaccines, it kept the same H1N1 choice but recommended A/Darwin/1415/2025 (H3N2)-like and B/Pennsylvania/14/2025 (B/Victoria lineage)-like viruses (technical document).

The split list is the first point readers need to understand. WHO did not publish two separate seasonal forecasts. It published one recommendation with platform-specific options for two components. That distinction matters because the source record shows WHO’s consultation is meant to guide different production methods, after experts review surveillance and other evidence from the Global Influenza Surveillance and Response System and other sources (WHO announcement; WER issue).

The strongest case for change in the retrieved records appears in the laboratory evidence summarized in the Weekly Epidemiological Record issue dated 16 October 2026. For A(H3N2), WHO said most analysed viruses belonged to subclade K, and antisera to the A/Darwin/1415/2025-like and A/Darwin/1454/2025-like viruses recognized recent J.2.4.2 and K viruses better than the Southern Hemisphere 2026 H3N2 reference viruses. For influenza B, WHO said all characterized viruses were B/Victoria lineage and that titres against many C.3.1 and C.3.3 viruses were reduced relative to older B/Austria/1359417/2021-like reference viruses (WER issue).

H1N1 is the more cautious part of the story. The same WER section says subclade D.3.1.1 predominated globally, yet post-vaccination haemagglutination inhibition geometric mean titres were significantly reduced for some recent D.3.1.1 viruses when compared with responses to A/Missouri/11/2025-like reference viruses in several human serum panels (WER issue). That is a laboratory warning sign, not proof of poor field performance. But it does show that keeping the Missouri-like H1N1 component was not the same as declaring the match problem solved (technical document).

What happens next is outside WHO’s direct control. WHO said its recommendations are used by national vaccine regulatory agencies and pharmaceutical companies to develop, produce and license vaccines, while the WER notes that national or regional authorities approve the composition and formulation used in each country (WHO announcement; WER issue). So 25 September 2026 marks a technical recommendation, not approval, rollout or a measured effectiveness result.

The remaining uncertainty is practical, not rhetorical. The technical document links candidate vaccine viruses and potency testing reagents, which are part of turning a recommendation into a product, but the retrieved records do not show later approval dates, production volumes, manufacturing yields, shipments or uptake (technical document). They also do not establish any 2027 season outcome. WHO’s 1 October 2026 EPI-WIN event page shows the organization planned a follow-up webinar on the evidence and posted five downloadable presentations, but as a schedule page written before the event, it cannot by itself confirm what was ultimately said or changed (event page).

That leaves a narrower, more useful conclusion. WHO has updated the strain targets for the 2027 Southern Hemisphere season, and the laboratory rationale is clearer for H3N2 and B/Victoria than for H1N1. But whether those recommendations become licensed doses on time, and how well they perform in use, remains a later question that these records do not answer.

How to read WHO’s flu vaccine recommendation. Two lists, one recommendation; Lab signals are not outcomes; What follows 25 September.
Original explanatory diagram. AI-assisted text and layout by Flor News Desk; based on the source records linked in this article. Flor News Desk